Exosomes, the tiny membrane-bound vesicles ranging from roughly 30 to 150 nanometers that cells naturally release to communicate with one another, have long been touted as ideal drug delivery vehicles. They are biocompatible, minimally immunogenic, and capable of crossing biological barriers that synthetic nanoparticles struggle with. The problem has always been cargo loading. Conventional techniques such as electroporation or passive co-incubation suffer from low encapsulation efficiency and can damage the delicate vesicle membrane, undermining function in vivo. The research team, led by investigators at Huazhong University of Science and Technology, sidestepped these issues entirely by exploiting a discovery from fundamental cell biology: mammalian cells sort specific RNAs into exosomes through sequence motifs that are recognized by RNA-binding proteins such as hnRNPA2B1. By appending these motifs to synthetic short hairpin RNAs, the researchers could coax producer cells into packaging therapeutic cargo into exosomes natively, without ever touching the vesicles with a loading device.

The engineering did not stop at cargo selection. A second bottleneck in exosome therapeutics is sheer quantity: parent cells rarely secrete enough vesicles for scalable manufacturing. Here the team turned to the Rab family of small GTPases, master regulators of intracellular vesicle trafficking. After systematically screening Rab family members, they found that silencing Rab4a in producer cells, specifically human umbilical vein endothelial cells used as the exosome factory, produced the largest boost in exosome output, an approximately 1.8-fold increase that outperformed silencing of Rab35 or Rab14. Mechanistically, Rab4 knockdown reduced the rapid recycling of early endosomes back to the plasma membrane, diverting membrane and cargo toward multivesicular body formation instead. Transmission electron microscopy confirmed a marked increase in multivesicular bodies and endosomal compartments, and Western blotting showed a roughly 2.6-fold rise in HGS, a core ESCRT pathway component that reflects exosome secretion capacity.

The resulting engineered exosomes, termed ExoM, were thoroughly characterized. Transmission electron microscopy revealed the classic cup-shaped, double-membrane morphology with diameters near 100 nanometers, and nanoparticle tracking analysis pegged the peak diameter at 107 nanometers. Positive markers of exosome identity, including TSG101, CD9, and CD63, were strongly enriched in the preparations, while the endoplasmic reticulum protein Calnexin, a negative marker, was depleted, confirming purity and correct biogenic origin. A tetracycline-inducible TetR-TetO switch gave the researchers temporal control over the expression system, allowing gene expression in the producer cells to be switched on with the small molecule trigger before exosome harvest by ultracentrifugation.

The cargo enrichment results were striking. The team designed four candidate RNA motifs and tested their ability to concentrate two therapeutic payloads, an shRNA targeting GPX4 and the tumor-suppressive microRNA miR-15a, inside exosomes. All four motifs outperformed unmodified controls, but the M1 motif, with the sequence CGGGAG, was the clear winner, achieving an 81.75-fold enrichment of shGPX4 and a 67.5-fold enrichment of miR-15a in secreted vesicles. Absolute quantitative PCR based on standard curves confirmed that these exosomes carried approximately 40,000 copies of each RNA per 100 million particles, concentrations the authors describe as therapeutically viable. Crucially, producer cells expressed the engineered RNAs at essentially identical levels regardless of motif, meaning the enrichment was a true sorting effect rather than a difference in transcription.

Rab4 silencing turned out to be a two-edged sword with both edges beneficial. The shRab4 carried within ExoM became part of the payload itself, delivered into recipient tumor cells where it began dismantling the recycling machinery. Fluorescence microscopy and flow cytometry tracked the consequences in Ishikawa endometrial cancer cells with remarkable temporal resolution. During the first four hours, engineered and control exosomes were internalized at nearly identical rates, indicating basal endocytosis was unaffected. But after roughly four to five hours, a divergence emerged: control exosome fluorescence plateaued and then declined as vesicles were recycled and expelled, while ExoM retention climbed steadily through eight hours. Rab4 protein levels in recipient cells began dropping by 12 hours and were near-completely depleted by 24 to 48 hours. The authors describe this as a priming effect, a feed-forward loop in which the first wave of exosomes disables the very recycling pathway that would otherwise eject subsequent doses.

To direct the platform to tumors, the researchers decorated the exosome surface with a DSPE-PEG2000-cRGD peptide that binds αvβ3 integrins, molecules overexpressed on endometrial cancer cells and tumor vasculature. The modification grew the particles from about 107 to roughly 146.5 nanometers in diameter, an increase attributed to the PEG chain and its hydration layer, but polydispersity indices remained well below 0.3 and the vesicles stayed stable for 48 hours in serum-containing medium at 37 degrees Celsius. In co-culture experiments mixing cancer cells with fluorescently labeled normal endothelial cells, cRGD-modified exosomes accumulated almost exclusively in the cancer cells, whereas unmodified vesicles distributed indiscriminately. In nude mice bearing xenograft tumors, in vivo imaging 48 hours after intravenous injection showed dramatically stronger fluorescence in tumors of animals receiving the cRGD-targeted vesicles.

The therapeutic payload was designed to strike at the heart of ferroptosis resistance. Prior work by the same group had established that endometrial cancer cells evade iron-dependent death by upregulating GPX4, FSP1, and ferritin heavy chain, three central antioxidants of the lipid peroxidation cascade. ExoM carries shRNAs against these targets, and treatment of Ishikawa cells measurably reduced all three at both mRNA and protein levels. The downstream biochemistry told a coherent ferroptotic story: malondialdehyde and reactive oxygen species rose, labile ferrous iron accumulated, and JC-1 staining revealed collapse of mitochondrial membrane potential. Most convincingly, co-treatment with Ferrostatin-1, a specific ferroptosis inhibitor, rescued cell viability, confirming that the cytotoxicity was genuinely ferroptosis-driven rather than a nonspecific toxic effect.

In vivo, the platform delivered where it mattered. Mice bearing subcutaneous Ishikawa tumors received tail-vein injections of PBS, unmodified exosomes, ExoM, a cRGD-modified exosome carrying scrambled RNA, or full cRGD-ExoM on days 3, 9, 15, and 21, and were euthanized on day 25. Tumors in the cRGD-ExoM group were significantly smaller and lighter than in all control groups, and the two partial controls, empty exosomes and scrambled-RNA vesicles, performed no better than saline, demonstrating that neither RNA machinery overload nor surface functionalization caused nonspecific harm. Tumor sections showed reduced Ki67 proliferation staining and depressed GPX4, FSP1, and FTH expression. Hematoxylin and eosin staining of lung, heart, liver, spleen, and kidney revealed no tissue damage, and serum ALT, AST, BUN, and creatinine levels remained within normal physiological ranges with no statistical differences among groups, an encouraging biosafety profile for a multi-component engineered nanomedicine.

The authors frame the work as a paradigm shift in which understanding intracellular trafficking directly informs therapeutic design, transforming exosomes from passive couriers into programmable nanobioreactors capable of spatially confined and temporally tunable ferroptosis induction. The platform builds on the group’s prior mechanistic studies of ferroptosis regulation in endometrial cancer, including findings on m6A modification, RAB17-mediated iron uptake control, and the circRAPGEF5-RBFOX2 axis, and it extends naturally toward combination strategies with immune checkpoint blockade or metabolic modulators, particularly in biomarker-negative tumors that respond poorly to current immunotherapy. Significant translation hurdles remain, including bioreactor-scale production, potency standardization, and pharmacokinetic tracking, but the convergence of RNA motif-guided cargo loading, Rab-controlled biomanufacturing, and integrin-targeted delivery offers a coherent roadmap for precision exosome nanomedicine in a cancer whose therapeutic options have, until now, been narrowing rather than expanding.

Subject of Research: Engineered exosome platform for targeted ferroptosis induction in endometrial carcinoma

Article Title: Engineered exosomes with RNA‐motif short hairpin RNA loading and Rab4‐boosted production enable controlled ferroptosis in endometrial carcinoma

Article References: Zhang, J., Yao, Y., Shu, W., Cheng, S., Zhong, G., Yu, J., Chen, J., Dong, K., Peng, Y., Zhang, J., & Wang, H. (2026). Engineered exosomes with RNA ‐motif short hairpin RNA loading and Rab4‐boosted production enable controlled ferroptosis in endometrial carcinoma. Bioengineering & Translational Medicine, Article e70163. https://doi.org/10.1002/btm2.70163

Image Credits: AI Generated

DOI: 10.1002/btm2.70163

Keywords: endometrial carcinoma, exosomes, ferroptosis, Rab4, RNA motifs, shRNA delivery, GPX4, cRGD targeting, nanomedicine, drug delivery, Engineered, motif

Ferroptosis is an iron-dependent, non-apoptotic form of cell death defined by the catastrophic accumulation of lipid peroxides in cellular membranes. Unlike apoptosis, which cancer cells frequently evade through well-characterized mutations, ferroptosis depends on the lipid composition of the cell, and one enzyme sits at the heart of that dependency: acyl-CoA synthetase long-chain family member 4, commonly abbreviated ACSL4. ACSL4 shapes the membrane pool of oxidizable polyunsaturated fatty acids, and cells with high ACSL4 levels are markedly more vulnerable to ferroptotic death. The new work demonstrates that pancreatic cancer cells actively destroy ACSL4 under hypoxic conditions, and that this destruction is orchestrated by an unexpected player drawn from the machinery of valine, an essential branched-chain amino acid.

The researchers began by comparing tumor samples from patients who responded to gemcitabine-based neoadjuvant chemotherapy with those from non-responders. Metabolomic and transcriptomic profiling revealed that valine, leucine, and isoleucine degradation was significantly enriched in non-responders, and within that pathway the gene encoding MMSDH, ALDH6A1, stood out for its association with poor treatment response and reduced disease-free survival. Transcription factor analysis traced elevated MMSDH expression to SP1, a transcription factor that binds the ALDH6A1 promoter in gemcitabine-resistant tumors, suggesting that the metabolic wiring of these cancers is rewired at the gene expression level before any drug ever enters the cell.

The mechanistic story then deepens in the oxygen-starved interiors of pancreatic tumors. Hypoxia, the researchers found, triggers an enzyme called GCN5 to install a lactyl group, a derivative of lactate, onto MMSDH at the amino acid lysine 113. This modification, known as lactylation, is part of a growing family of metabolite-driven protein modifications that have recently been shown to regulate DNA repair, chromatin biology, and now cancer metabolism. Lactylated MMSDH physically interacts with ACSL4 and, through its catalytic activity, generates propionyl-CoA, a short-chain acyl intermediate of valine catabolism. That propionyl-CoA is then handed to another acetyltransferase, KAT8, which uses it to attach a propionyl group to ACSL4 at lysine 606.

The consequences of this single chemical mark are profound. Propionylation at K606 repositions ACSL4 so that it binds HSC70, the cytosolic chaperone that recognizes the KFERQ-like targeting motifs required for chaperone-mediated autophagy, a selective degradation pathway in which individual proteins are unfolded and threaded into lysosomes. Once flagged in this way, ACSL4 is destroyed, its lipid-remodeling activity collapses, and the tumor cell becomes resistant to the lipid peroxidation that gemcitabine otherwise promotes. Using mass spectrometry, the team confirmed both the K113 lactylation on MMSDH and the K606 propionylation on ACSL4 in hypoxic pancreatic cancer cells, and showed that mutant versions of these proteins that cannot be modified fail to drive ACSL4 degradation or protect cells from ferroptotic death induced by gemcitabine, erastin, or RSL3.

Critically, the findings are not confined to cell culture. In an analysis of patient cohorts, tumors harboring high levels of MMSDH K113 lactylation and ACSL4 K606 propionylation displayed low ACSL4 protein, heightened ferroptosis resistance, and poor clinical response to neoadjuvant chemotherapy. Mouse xenograft experiments extended the picture: tumor cells engineered to express non-modifiable mutants of MMSDH or ACSL4 lost their protective shield and became acutely vulnerable to gemcitabine, while cells bearing the modification-enhancing wild-type enzymes grew aggressively even under low-oxygen conditions and responded poorly to treatment. The team also showed that the same axis operates in lung and ovarian cancer cell lines, hinting that MMSDH-mediated ACSL4 propionylation may be a broader mechanism of ferroptosis evasion across solid tumors.

Perhaps the most translational aspect of the study lies in two therapeutic strategies the authors developed to disrupt this axis. The first is dietary: because MMSDH is a valine catabolism enzyme that depends on valine-derived substrate to generate propionyl-CoA, restricting dietary valine in mice starved the pathway of its fuel. Combining valine-restricted diets with gemcitabine synergistically restored lipid peroxidation and suppressed tumor growth, notably without causing significant toxicity, weight loss, or metabolic distress in the animals. The second approach is pharmacological: the team designed cell-penetrating blocking peptides centered on the lactylated K113 sequence of MMSDH. A lead peptide disrupted the interaction between lactylated MMSDH and ACSL4, prevented ACSL4 propionylation and degradation, restored ferroptotic sensitivity, and markedly potentiated gemcitabine in both subcutaneous and orthotopic pancreatic tumor models while improving animal survival.

Beyond the immediate therapeutic implications, the study expands the conceptual map of how post-translational modifications couple cellular metabolism to cell fate. Amino acid catabolic enzymes are increasingly appreciated as moonlighting regulators of signaling and protein stability, and this work adds a new chapter by showing that a valine-processing enzyme can be co-opted by hypoxia-driven lactylation to flag a ferroptosis gatekeeper for lysosomal destruction. It also illustrates a chemical relay of remarkable economy: hypoxia produces lactate, lactate lactylates MMSDH, lactylated MMSDH produces propionyl-CoA from valine, and propionyl-CoA propionylates ACSL4, linking three metabolic programs, glycolysis, branched-chain amino acid catabolism, and lipid metabolism, into a single survival circuit. The authors’ clinical data suggest that MMSDH K113 lactylation and ACSL4 K606 propionylation may serve as biomarkers for predicting which pancreatic cancer patients will benefit from gemcitabine-based neoadjuvant regimens, potentially guiding treatment selection in a disease where therapeutic options remain painfully limited.

Challenges remain before this biology reaches the clinic. Blocking peptides must be optimized for delivery, stability, and specificity in humans, and dietary valine restriction will need careful evaluation in clinical trials, particularly given the catabolic state of many pancreatic cancer patients. Yet the study provides something pancreatic oncology has long needed: a mechanistically resolved, chemically validated, and clinically correlated explanation for why so many tumors shrug off chemotherapy, together with concrete tools to break that resistance. By exposing the GCN5-MMSDH-ACSL4 axis, the Zhejiang University team has turned a metabolic quirk of hypoxic tumor cells into a target, and in doing so opened a plausible path toward making ferroptosis-inducing chemotherapy a reality for one of medicine’s most intractable cancers.

Subject of Research: Hypoxia-driven MMSDH lactylation and ACSL4 propionylation as a mechanism of ferroptosis evasion and chemotherapy resistance in pancreatic ductal adenocarcinoma

Article Title: MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

Article References: MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy. (n.d.). https://doi.org/10.1038/s43018-026-01236-w

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01236-w

Keywords: pancreatic ductal adenocarcinoma, ferroptosis, MMSDH, ACSL4, lactylation, propionylation, hypoxia, gemcitabine resistance, chaperone-mediated autophagy, valine metabolism, GCN5, KAT8

Radiation therapy remains a cornerstone in the clinical management of lung cancer, yet its effectiveness is frequently compromised by the tumor cells’ capacity to develop resistance. While DNA damage induction and apoptosis have long been recognized as primary mechanisms through which radiation exerts its cytotoxic effects, recent advances have highlighted ferroptosis as another vital modality of radiation-induced cell death. Ferroptosis involves iron-dependent lipid peroxidation leading to cell membrane damage, a process that tumor cells can circumvent to ensure survival. Dr. Gan’s team focused on unraveling how lung cancer cells evade ferroptosis, thereby contributing to treatment failure.

At the heart of this resistance mechanism lies DHODH, a mitochondrial enzyme well-known for its role in de novo pyrimidine biosynthesis, essential for RNA and DNA synthesis. The researchers discovered that increased DHODH activity not only supports the synthesis of nucleotides needed for DNA repair after radiation-induced damage but also leads to the production of ubiquinol, a powerful antioxidant molecule that inhibits ferroptosis by preventing lipid peroxidation. This dual functionality of DHODH positions it as a central player in facilitating tumor cell survival under the assault of radiation therapy.

This insight propelled the hypothesis that inhibiting DHODH could dismantle the cancer cells’ defense against ferroptosis, restoring their susceptibility to radiation-induced death. Fortunately, leflunomide, an FDA-approved drug primarily prescribed for rheumatoid arthritis, is a known DHODH inhibitor. The study leveraged leflunomide to examine its potential to sensitize lung tumors to radiation, providing immediate translational appeal given the drug’s established clinical approval.

Yet, the story does not end with the DHODH inhibitor alone. The research team designed an innovative triple combination therapy that integrates radiation therapy with immune checkpoint blockade—a form of immunotherapy utilizing anti-PD-1 antibodies—to potentiate the killing of radioresistant lung cancer cells. Although the binary combination of radiation and immunotherapy was insufficient to halt tumor progression in preclinical models, it primed the tumor microenvironment by inducing interferon-gamma (IFN-γ), a cytokine known to promote ferroptosis.

Incorporating leflunomide into this regimen disrupted DHODH-driven ferroptosis suppression, thereby allowing the cancer cells to succumb to lipid peroxidation-induced death. The triple combination exhibited a synergistic effect, re-sensitizing lung tumors to radiation and overcoming prior resistance that limited therapeutic outcomes. Dr. Gan emphasized that while DHODH inhibition alone modestly enhanced radiosensitivity, it was the integrative approach that yielded robust anti-tumor responses.

The mechanistic insights revealed by this study stitch together complex biochemical pathways involving mitochondrial metabolism, immune modulation, and cell death regulation. The upregulation of DHODH serves a protective role by ensuring a supply of pyrimidine nucleotides essential for DNA repair processes and by generating ubiquinol to neutralize oxidative stress from lipid peroxidation. Simultaneously, the immune-stimulating environment created by checkpoint inhibitors and radiation-induced IFN-γ amplifies ferroptosis signaling, creating a therapeutic window exploitable by DHODH inhibition.

These findings resonate beyond lung cancer, as ferroptosis resistance is increasingly acknowledged in various malignancies and therapeutic contexts. The identification of DHODH as a suppressor of ferroptosis not only elucidates a fundamental resistance pathway but also offers an actionable target harnessed by exploiting existing pharmacological agents. Leflunomide’s repositioning as a radiosensitizer exemplifies the power of translational research bridging molecular discovery with clinical potential.

Importantly, the preclinical nature of this research underscores the need for clinical trials to validate the safety, optimal dosing, and efficacy of this triple combination therapy in human patients. However, the immediacy of translational prospects that FDA approval of leflunomide affords positions this strategy for rapid clinical evaluation. This study exemplifies precision oncology’s trajectory toward dissecting resistance mechanisms and developing targeted interventions to improve cancer therapy outcomes.

The multi-institutional research team received support from several prestigious funding agencies, including the National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas (CPRIT), underlining the broad scientific acknowledgment of this work’s significance. Their published article in the American Association for Cancer Research’s journal Cancer Research offers an extensive account of the experimental design, molecular analyses, and therapeutic implications, setting a foundation for further exploration in ferroptosis biology and mitochondrial metabolism within oncology.

In the relentless battle against lung cancer, the discovery of DHODH’s role in ferroptosis suppression and radiation resistance shines a beacon on new therapeutic horizons. Combining radiotherapy with immunomodulation and targeted metabolic inhibition produces a formidable triad that could revolutionize treatment paradigms for patients plagued by resistant tumors. As precision medicine evolves, studies like Dr. Gan’s propel the field toward more effective, tailored interventions that overcome resistance and improve survival outcomes.

This pioneering work not only enriches the scientific understanding of radioresistance mechanisms but also vividly illustrates the translational potential that lies in repurposing existing drugs to tackle unmet clinical challenges. The integration of metabolic inhibitors with immunotherapy and radiotherapy heralds a new chapter in cancer treatment strategies, ushering hope for improved efficacy against formidable malignancies like lung cancer.

Subject of Research: Animals
Article Title: DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer Available
News Publication Date: 8-Apr-2026
Web References: https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-3728
References: DOI 10.1158/0008-5472.CAN-25-3728
Image Credits: The University of Texas MD Anderson Cancer Center
Keywords: Radiation therapy, lung cancer, DHODH, ferroptosis, radioresistance, leflunomide, immunotherapy, immune checkpoint blockade, anti-PD-1, interferon-gamma, mitochondrial metabolism, cancer treatment

The enigmatic nature of breast cancer progression has long intrigued researchers seeking to identify the pathways that facilitate the malignancy’s aggressive nature. TFAP2C, a member of the transcription factor AP-2 family, should be viewed as a pivotal player in this biological drama. Its role extends beyond merely influencing gene expression—TFAP2C orchestrates a myriad of cellular responses that can either foster or hinder cancer development. By activating CST1 transcription, TFAP2C was initially thought to create an environment conducive to tumor growth, manipulating the cancer cell’s innate machinery for its advantage.

Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, has recently emerged as a critical area of focus in cancer research. Unlike apoptosis, which plays a well-documented role in cancer, ferroptosis presents a unique set of challenges for malignancies. The initial hypothesis posited that the activation of CST1 through TFAP2C would suppress this lethal mechanism, allowing cancer cells to survive in harsh environmental conditions, thus propelling the progression of breast cancer. This process, believed to blur the lines between cell survival and death, has captured the attention of oncologists and cell biologists alike.

Upon further scrutiny, the research team comprising Yuan, Zhou, and Li found compelling evidence linking the transcriptional activity of TFAP2C to the regulation of CST1. This relationship was underscored by a series of experiments that indicated a direct correlation not only between the presence of TFAP2C and CST1 levels but also between CST1 expression and enhanced tumor aggressiveness. Moreover, the intricate interplay between these components appeared to confer a survival advantage to the cancer cells, raising the stakes for targeted therapeutic interventions.

However, the clarity offered by these findings rapidly faded when a retraction was issued, questioning the data’s robustness. Such occurrences are not uncommon in the scientific community, where preliminary findings undergo rigorous peer review and experimental validation. The retraction serves as a cautionary tale, emphasizing the necessity for reproducibility in science, particularly in studies that have significant implications for clinical applications. While the initial study purported to shed light on the mechanisms underlying breast cancer, the subsequent withdrawal of its findings leaves a gap in the understanding that researchers must now grapple with.

The fallout from the retraction extends beyond theoretical implications; it also casts a long shadow over ongoing research and regulatory pathways. Pharmaceutical companies and research institutions readily monitor breakthroughs with the potential for therapeutic development, and a retracted study can slow momentum. Researchers now find themselves at a crossroads, needing to reassess their methodologies and validate findings independently, especially when proposing novel cancer therapies.

Importantly, this incident raises critical questions regarding the peer review process and the accountability of researchers. It illustrates the delicate balance that exists between the excitement of discovery and the commitment to scientific integrity. As the community collectively processes this debacle, a renewed emphasis on methodological rigor will likely emerge. By implementing stronger oversight protocols, the scientific community can enhance the reliability of findings that ultimately shape the future of cancer treatment.

Moving forward, one can appreciate the complexity of biochemical interactions at play in cancer malignancy. The role of TFAP2C as a potential therapeutic target may continue to be explored, provided future studies adopt a more robust experimental design. Researchers may wish to delve deeper into the relationship between TFAP2C and CST1, employing multifaceted approaches that include genetic modeling and biochemical assays to reinforce their findings.

It is also crucial for upcoming studies to remain vigilant about the phenomena of ferroptosis and its regulatory mechanisms. Understanding how various factors modulate this form of cell death could reveal novel angles for cancer therapy, particularly in cancers known for their resistance to conventional treatments. In this context, every setback must be treated as an opportunity for scientific growth and discovery.

Finally, as the dust settles on this retraction, one can only hope that the lessons learned will stimulate new inquiries and inspire more resilient scientific practices. The truth about cancer is often elusive, but the pursuit of knowledge must persist. Through tireless research and stringent verification, the scientific community can work towards illuminating even the darkest corners of cancer biology. In the end, it is the collaborative effort among researchers, clinicians, and patients that will fuel innovation and ultimately lead to breakthroughs in our fight against cancer.

Overall, this incident serves as a profound reminder of the complexities inherent in biomedical research and the necessity of critical examination of the science we consume. As we strive to unlock the secrets of cancer, a commitment to ethical practices and high-quality research will be paramount in our collective goal to combat this formidable disease.

Subject of Research: TFAP2C and its role in breast cancer progression and ferroptosis suppression.

Article Title: Retraction Note: TFAP2C Activates CST1 Transcription to Facilitate Breast Cancer Progression and Suppress Ferroptosis.

Article References:

Yuan, L., Zhou, D., Li, W. et al. Retraction Note: TFAP2C Activates CST1 Transcription to Facilitate Breast Cancer Progression and Suppress Ferroptosis. Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11267-0

Image Credits: AI Generated

DOI:

Keywords: TFAP2C, CST1, breast cancer, ferroptosis, transcription factors, cancer progression, retraction, scientific integrity.